Business
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now underway in its Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous (IV) Choline Chloride in patients receiving long-term parenteral support (PS). IV Choline Chloride, the Company’s investigational phospholipid substrate replacement therapy, wa
About this update from Protara Therapeutics, Inc.
[{"type":"image","alt":"Protara Therapeutics","displaySize":"","headline":null,"caption":"Protara Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UG_sFiObOKNigh1f.P_1zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72","width":300,"height":106}},"lazy":false},{"type":"text","content":"NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now underway in its Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous (IV) Choline Chloride in patients receiving long-term parenteral support (PS). IV Choline Chloride, the Company’s investigational phospholipid substrate replacement therapy, was previously granted Fast Track designation by the U.S. Food and Drug Administration.","length":585,"tagName":"p"},{"type":"text","content":"“Choline deficiency, which can lead to serious hepatic injury, neuropsychological impairment, muscle damage, and thrombotic abnormalities, has been shown to impact 78% of patients dependent on PS, yet there are currently no approved IV choline products globally to address this pressing need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We believe that IV Choline Chloride has the potential to make a meaningful impact in this highly underserved population and could ultimately become the first FDA-approved IV choline therapy for patients dependent on PS. We look forward to advancing this important study and expect to provide an interim analysis from the trial in the second half of 2026.”","length":722,"tagName":"p"},{"type":"text","content":"THRIVE-3 (NCT06910943) is a seamless Phase 2b/3 trial designed to assess the efficacy and safety of low and high dose IV Choline Chloride in adolescent and adult patients receiving long-term PS when oral or enteral nutrition is not possible, insufficient, or contraindicated. Following an 8-week Phase 2b open-label, dose-confirmation trial in 24 patients, approximately 105 additional patients will be enrolled in a 24...